Marisa Wexler, MS,  senior science writer—

At ANCA Vasculitis News, we have spent the last year bringing you coverage of the latest developments in research and treatment for ANCA-associated vasculitis (AAV). Here, we’ve compiled a list of the top 10 most-read articles of 2023, with a brief description of each. We look forward to…

Self-reactive anti-neutrophil cytoplasmic antibodies, or ANCAs, may play a unique role in driving blood vessel inflammation in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest form of ANCA-associated vasculitis (AAV). That’s according to a small study, which found that disease relapses outside the respiratory system occurred only in EGPA…

In a Phase 3 trial of Tavneos (avacopan) in people with ANCA-associated vasculitis (AAV), the therapy’s effectiveness in the subgroup of patients on standard induction treatment with rituximab was similar to that of the overall study population. Reasonable safety also was seen, and sustained one-year remission was higher…

The U.S. Food and Drug Administration has approved Sana Biotechnology’s investigational new drug (IND) application requesting a Phase 1 clinical trial of its investigational cell therapy SC291 in people with ANCA-associated vasculitis (AAV) and other autoimmune diseases. “Our goal is to develop SC291 for patients with multiple…

People with ANCA-associated vasculitis (AAV) that affects their kidneys are at a significantly increased risk of kidney failure if they show a high proportion of inflamed glomeruli (the organ’s filtering units) on biopsies collected at diagnosis, a study has found. The study, “Renal histopathological predictors of…

High blood levels of the immune protein C4 are significantly associated with greater kidney-specific disease activity and a higher chance of developing kidney failure with microscopic polyangiitis (MPA), the most common type of ANCA-associated vasculitis (AAV), a study shows. For this reason, measuring blood C4 levels may help predict…

A treatment regimen that combines low-dose glucocorticoids and rituximab is just as effective at controlling ANCA-associated vasculitis (AAV) as a standard regimen of high-dose glucocorticoids and rituximab, according to two-year data from a clinical trial. The long-term findings indicate that, while the efficacy is comparable, the risk of serious…

Researchers in Korea have developed a new system to classify ANCA-associated vasculitis (AAV) into clusters, and provided an algorithm that can be used for such classification in future clinical studies. “This simple algorithm can incorporate any patient with atypical or nonspecific symptoms and can be easily modified to identify…

Subclinical changes are evident in the small blood vessels in the back of the eye and in the nails of people with ANCA-associated vasculitis (AAV) that are not associated with overt eye or nail symptoms, a study showed. Notably, a reduced blood vessel density in patients’ eyes, assessed via…

The prognostic immune nutritional index or PINI — a novel clinical tool based on counts of immune cells and levels of a blood protein called albumin — can be used to help predict the risk of death in people with ANCA-associated vasculitis (AAV), a new study shows. For serious…